Cysteamine-induced depletion of somatostatin and prolactin.
Cysteamine (2-aminoethanethiol [CSH], given in vivo or in vitro, rapidly but reversibly depletes immunoreactive somatostatin (irSS) in the central nervous system and gut as well as biological and immunological prolactin (PRL) activity in both the anterior pituitary and blood of the rat. This depletion of irSS and PRL is dose dependent and cannot be accounted for by release of either compound. Basal and potassium-stimulated SS release is reduced from hypothalamic tissue in vitro in CSH-treated animals. PRL secretion induced both pharmacologically and physiologically is abolished after CSH administration. Furthermore, CSH reduces cellular PRL content in a number of hyperprolactinemic states. The mechanism by which CSH reduces PRL levels is not clear, but it does not appear to act through the dopamine receptor nor does it alter the morphological structure of the lactotrope in normal animals. Most likely, CSH acts by interacting with the disulfide bonds of PRL, thus rendering the molecule both immunologically and biologically inactive.
Millard
W J
WJ
Sagar
S M
SM
Martin
J B
JB
D000818:Animals; D002490:Central Nervous System / Q000378:metabolism; D003543:Cysteamine / Q000494:pharmacology*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D009374:Neoplasms, Experimental / Q000503:physiopathology; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D011388:Prolactin / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D011555:Pseudopregnancy / Q000503:physiopathology; D051381:Rats; D013004:Somatostatin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000494:pharmacology
D013438:Sulfhydryl Compounds; D013004:Somatostatin; D003543:Cysteamine; D011388:Prolactin